The Journey of Warfarin

Warfarin is rapidly and nearly completely absorbed from the
gastrointestinal tract (bioavailability ~99%), reaching peak plasma concentrations within 2-4 hours
after oral dosing. It is available as the sodium salt. Absorption occurs primarily in the small
intestine and is not significantly affected by food or co-administered antacids. The high absorption
efficiency makes parenteral formulations unnecessary and oral dosing highly reliable in terms of
pharmacokinetic input. The drug is administered as a racemic mixture of R- and S-warfarin enantiomers
(50:50 ratio). S-warfarin is approximately 3-5 times more pharmacologically potent than R-warfarin
and is the primary focus of drug interaction analysis.

Warfarin is extensively protein-bound — over 99% to plasma albumin
— resulting in a very small volume of distribution (approximately 0.1-0.2 L/kg). Because virtually
all drug is albumin-bound, it is largely confined to plasma and does not penetrate cells readily.
However, in the liver, warfarin dissociates from albumin and enters hepatocytes where it exerts
its pharmacological effect. The drug crosses the placenta readily and is embryotoxic during the
first trimester (warfarin embryopathy), fetotoxic (intracranial hemorrhage) in the third trimester,
and is therefore contraindicated throughout pregnancy for most indications. Warfarin does not
penetrate the blood-brain barrier significantly. Drugs that displace warfarin from albumin
(e.g., sulfamethoxazole) can transiently increase free drug levels and anticoagulant effect.

Warfarin acts by inhibiting vitamin K epoxide reductase complex 1
(VKORC1), a multisubunit transmembrane protein in the endoplasmic reticulum of hepatocytes.
VKORC1 catalyzes the reduction of vitamin K 2,3-epoxide to vitamin K quinone, and further to
the active hydroquinone form (KH2). KH2 is the essential cofactor for gamma-glutamyl carboxylase,
which carboxylates glutamate residues on vitamin K-dependent clotting factors (II, VII, IX, X)
and anticoagulant proteins (C and S), enabling them to bind calcium and phospholipid membranes
to participate in coagulation. By blocking vitamin K recycling, warfarin gradually depletes
carboxylated (functional) clotting factors. The onset of anticoagulation is delayed (48-72 hours
for measurable INR change, 5-7 days for full effect) because it depends on clearance of
pre-existing carboxylated factors — most importantly factor VII (shortest half-life ~6 hours)
followed by protein C (8 hours), factor IX (24 hours), factor X (40 hours), and factor II
prothrombin (72 hours). VKORC1 also reduced vitamin K quinone to KH2, explaining warfarin's
full effect on all vitamin K-dependent proteins.

Warfarin's metabolism is complex because the R and S enantiomers
are processed differently. S-warfarin is primarily metabolized by CYP2C9 to 7-hydroxywarfarin
(inactive). R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19 to multiple hydroxylated
metabolites. CYP2C9 genetic polymorphisms profoundly affect warfarin dose requirements: CYP2C9*2
and CYP2C9*3 variants reduce enzyme activity by 30% and 90%, respectively, requiring significantly
lower warfarin doses to avoid hemorrhagic complications. Similarly, VKORC1 polymorphisms affect
target sensitivity to warfarin. FDA-cleared pharmacogenomic dosing algorithms incorporate CYP2C9
and VKORC1 genotypes, body surface area, and clinical variables to calculate starting doses.

Warfarin metabolites are excreted primarily in urine (60-92%)
and to a lesser extent in feces. The plasma half-life of the racemic mixture is 20-60 hours
(average ~40 hours). The half-life of S-warfarin (the more potent enantiomer) is shorter (25-30
hours) than R-warfarin (35-45 hours). The long half-life necessitates days to reach steady state
and days to reverse anticoagulation after dose changes — important when switching to heparin before
procedures or when managing bleeding complications. Vitamin K administration accelerates recovery
by providing substrate to overcome the VKORC1 blockade.

Warfarin has the narrowest therapeutic index of any widely used oral
drug, with therapeutic INR 2.0-3.0 (2.5-3.5 for mechanical heart valves). Over 100 drug interactions
are documented, with CYP2C9 inhibitors (amiodarone, fluconazole, metronidazole) and inducers
(rifampicin, carbamazepine, St John's wort) being most important. Amiodarone — a potent CYP2C9
inhibitor — can double INR. Dietary vitamin K intake variability (green leafy vegetables) is a
major source of INR instability. Direct oral anticoagulants (DOACs) have largely replaced warfarin
for atrial fibrillation and VTE, but warfarin remains preferred for mechanical heart valves.